skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma

Abstract

A new radiopharmaceutical, I-131 metaiodobenzylguanidine (I-131 MIBG) was used to determine the location and to follow-up tumors in a 13-month-old girl with neuroblastoma. I-131 MIBG imaging revealed both a primary abdominal tumor and a distant metastatic orbital tumor. Follow-up study with I-131 MIBG imaging demonstrated significant resolution of tumors after external radiotherapy and chemotherapy. I-131 MIBG imaging is a simple, safe, and specific method of determining the location of tumors and also is clinically useful in the evaluation and management of patients with neuroblastoma.

Authors:
; ; ; ; ; ; ;
Publication Date:
Research Org.:
Kobe General Hospital, Japan
OSTI Identifier:
6796487
Alternate Identifier(s):
OSTI ID: 6796487
Resource Type:
Journal Article
Resource Relation:
Journal Name: Clin. Nucl. Med.; (United States); Journal Volume: 11
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ABDOMEN; NEOPLASMS; RADIOISOTOPE SCANNING; DIAGNOSIS; IODINE 131; METASTASES; PATIENTS; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BODY; BODY AREAS; COUNTING TECHNIQUES; DAYS LIVING RADIOISOTOPES; DISEASES; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOTOPES; NUCLEI; ODD-EVEN NUCLEI; RADIOISOTOPES 550601* -- Medicine-- Unsealed Radionuclides in Diagnostics

Citation Formats

Ikekubo, K., Habuchi, Y., Jeong, S., Yamaguchi, H., Saiki, Y., Ito, H., Hino, M., and Higa, T. Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma. United States: N. p., 1986. Web. doi:10.1097/00003072-198611000-00012.
Ikekubo, K., Habuchi, Y., Jeong, S., Yamaguchi, H., Saiki, Y., Ito, H., Hino, M., & Higa, T. Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma. United States. doi:10.1097/00003072-198611000-00012.
Ikekubo, K., Habuchi, Y., Jeong, S., Yamaguchi, H., Saiki, Y., Ito, H., Hino, M., and Higa, T. Sat . "Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma". United States. doi:10.1097/00003072-198611000-00012.
@article{osti_6796487,
title = {Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma},
author = {Ikekubo, K. and Habuchi, Y. and Jeong, S. and Yamaguchi, H. and Saiki, Y. and Ito, H. and Hino, M. and Higa, T.},
abstractNote = {A new radiopharmaceutical, I-131 metaiodobenzylguanidine (I-131 MIBG) was used to determine the location and to follow-up tumors in a 13-month-old girl with neuroblastoma. I-131 MIBG imaging revealed both a primary abdominal tumor and a distant metastatic orbital tumor. Follow-up study with I-131 MIBG imaging demonstrated significant resolution of tumors after external radiotherapy and chemotherapy. I-131 MIBG imaging is a simple, safe, and specific method of determining the location of tumors and also is clinically useful in the evaluation and management of patients with neuroblastoma.},
doi = {10.1097/00003072-198611000-00012},
journal = {Clin. Nucl. Med.; (United States)},
number = ,
volume = 11,
place = {United States},
year = {Sat Nov 01 00:00:00 EST 1986},
month = {Sat Nov 01 00:00:00 EST 1986}
}
  • Our experience in scintigraphic diagnosis using /sup 123/I//sup 131/I-metaiodobenzylguanidine (MIBG) on 37 children with neuroblastomas stage III-IV is reported and discussed, together with the results obtained by other authors on MIBG diagnosis at the International Workshop of Pediatric Oncology held in Rome in September 1986. In our own investigation, 49 examinations were undertaken with /sup 123/I-MIBG and 66 with /sup 131/I-MIBG partly under therapy conditions with high-activity doses of /sup 131/I-MIBG. There were 29 neuroblastomas, 3 ganglioneuromas, and 3 ganglioneuroblastomas. The localization of all primary tumors was over 90%; for neuroblastomas with a high level of catecholamine excretion, over 95%.more » The specificity was about 100%. The sensitivity with respect to tumor relapse and all localization of metastasis and bone-marrow tumor infiltration in the follow-up-phase approaches was 70% during or after therapy. What emerges from the experience of most investigators is that /sup 123/I-MIBG is the agent best suited to detect tumor relapse and metastasis, especially in the bone marrow. MIBG examinations are of great value in follow-up studies for detecting tumor relapse and bone marrow infiltrations, especially before the onset of clinical symptoms and other indications. 16 references.« less
  • Localization of either multiple, metastatic and/or asymptomatic pheochromocytomas sometimes is elusive because all imaging methods to date have been nonspecific in character. The authors report 2 cases in which scintigraphy was used with a new radiopharmaceutical agent, /sup 131/iodine-metaiodobenzylguanidine, for the accurate localization of pheochromocytoma. To the best of our knowledge, this is the first report of asymptomatic pheochromocytoma imaged by /sup 131/iodine-metaiodobenzylguanidine scintigraphy.
  • Ten patients with histologically proven neuroblastoma were studied by (/sup 131/I)MIBG scintigraphy. Tumor uptake of the radiopharmaceutical showed a spectrum varying from no uptake in one case, to slight uptake in two, moderate uptake in two and intense uptake in five cases. Iodine-131 MIBG scintigraphy was more effective in demonstrating the extent of neuroblastoma spread than were conventional bone scan and CT in one patient, equal to these modalities in four cases, almost equal in two cases and significantly inferior in three cases. These preliminary results suggest that (/sup 131/I)MIBG scintigraphy is useful in detecting the presence and delineating themore » distribution of neuroblastoma and may, in certain cases, have therapeutic potential.« less
  • Effects of high activities of I 131 meta-iodobenzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty-two doses of mIBG labeled with 1.3 to 4 GBq (35-108 mCi) of iodine 131 were administered. Three subjective effects, especially relief of pain, and two objective effects were observed. Transient blood pressure increase was observed once and did not recur after prolongation of the infusion time to 6 hours. A major side effect was bone marrow toxicity, essentially marked by thrombopenia, particularly severe in previously bone-marrow-transplantedmore » patients.« less
  • Eight patients affected by neuroblastoma were treated with 18 courses of /sup 131/I-meta-iodobenzylguanidine (MIBG). They all had been judged as nonresponders to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow depression; one, whose marrow had been previously purged by chemotherapy, showed a decrease in blood cell counts but not to critical levels, thus allowing repeated treatments and some improvement. Two other cases had stage III disease, without marrow involvement. Both could receive repeated treatments without adverse effects on marrow and circulating blood cells; both could have surgicalmore » procedures when a significant neoplastic mass reduction had been induced by MIBG treatments. Almost all patients experienced reduction or disappearing of pain. Treatments were well tolerated.« less